NYSEAMERICAN:MTNB - Matinas BioPharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.03 +0.01 (+0.98 %)
(As of 02/21/2019 04:00 PM ET)
Previous Close$1.02
Today's Range$0.98 - $1.05
52-Week Range$0.32 - $1.48
Volume424,300 shs
Average Volume981,914 shs
Market Capitalization$115.76 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. The company's lead anti-fungal product candidate is MAT2203, an orally-administered cochleate formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients with acute lymphoblastic leukemia. Its product candidates also comprise MAT2501, an orally administered cochleate formulation of the broad spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. The company was founded in 2013 and is based in Bedminster, New Jersey.

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:MTNB
CUSIPN/A
CIKN/A
Phone+1-908-4431860

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees15
Market Cap$115.76 million
Next Earnings Date3/25/2019 (Estimated)
OptionableNot Optionable

Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) released its quarterly earnings results on Friday, August, 10th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.04). The firm had revenue of $0.09 million for the quarter. View Matinas BioPharma's Earnings History.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release their next quarterly earnings announcement on Monday, March 25th 2019. View Earnings Estimates for Matinas BioPharma.

What price target have analysts set for MTNB?

2 analysts have issued 12 month target prices for Matinas BioPharma's stock. Their predictions range from $4.75 to $5.00. On average, they expect Matinas BioPharma's stock price to reach $4.8750 in the next twelve months. This suggests a possible upside of 373.3% from the stock's current price. View Analyst Price Targets for Matinas BioPharma.

What is the consensus analysts' recommendation for Matinas BioPharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Matinas BioPharma.

Has Matinas BioPharma been receiving favorable news coverage?

Media stories about MTNB stock have trended somewhat positive on Thursday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Matinas BioPharma earned a news impact score of 1.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a increase in short interest in January. As of January 31st, there was short interest totalling 5,721,565 shares, an increase of 25.7% from the January 15th total of 4,550,674 shares. Based on an average trading volume of 961,409 shares, the days-to-cover ratio is currently 6.0 days. Currently, 6.0% of the company's shares are short sold. View Matinas BioPharma's Current Options Chain.

Who are some of Matinas BioPharma's key competitors?

What other stocks do shareholders of Matinas BioPharma own?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the folowing people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 45)
  • Mr. Keith A. Kucinski CPA, Chief Financial Officer (Age 48)
  • Dr. Raphael J. Mannino, Sr. VP & Chief Scientific Officer (Age 72)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 52)
  • Mr. Frank Calamusa, Exec. Director and Head of Manufacturing & Supply Chain

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include IFP Advisors Inc (1.58%), Raymond James Financial Services Advisors Inc. (0.73%), BlackRock Inc. (0.26%), Northern Trust Corp (0.16%), Virtu Financial LLC (0.06%) and Private Advisor Group LLC (0.04%). Company insiders that own Matinas BioPharma stock include Adam K Stern, James S Scibetta and Roelof Rongen. View Institutional Ownership Trends for Matinas BioPharma.

Which major investors are selling Matinas BioPharma stock?

MTNB stock was sold by a variety of institutional investors in the last quarter, including Raymond James Financial Services Advisors Inc.. View Insider Buying and Selling for Matinas BioPharma.

Which major investors are buying Matinas BioPharma stock?

MTNB stock was purchased by a variety of institutional investors in the last quarter, including IFP Advisors Inc, BlackRock Inc., Virtu Financial LLC, D. E. Shaw & Co. Inc., Northern Trust Corp and Private Advisor Group LLC. Company insiders that have bought Matinas BioPharma stock in the last two years include Adam K Stern, James S Scibetta and Roelof Rongen. View Insider Buying and Selling for Matinas BioPharma.

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $1.03.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $115.76 million. Matinas BioPharma employs 15 workers across the globe.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is http://www.matinasbiopharma.com/.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.


MarketBeat Community Rating for Matinas BioPharma (NYSEAMERICAN MTNB)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  167 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  299
MarketBeat's community ratings are surveys of what our community members think about Matinas BioPharma and other stocks. Vote "Outperform" if you believe MTNB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTNB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Featured Article: What is a balanced fund?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel